Text Size: a  |   a 

Laquinimod Fails to Meet Primary Clinical Trial Goal of Slowing Progression of RRMS

May 12, 2017

Laquinimod, also known as Nerventra or ABR-215062, failed to meet its primary Phase 3 clinical trial objective of slowing the progression of relapsing-remitting multiple sclerosis (RRMS) after three months. The developers of this drug is Teva Pharmaceutical Industries and Active Biotech. This has prompted the partners to abandon their quest to use the therapy to treat RRMS. Laquinimod targets neurodegenerative-tissue inflammation and degeneration. It was developed with the idea it could treat neurodegenerative condition besides RRMS, including primary progressive multiple sclerosis (PPMS) and Huntington’s disease.

Researchers were disappointment when results showed that the progression of the disease in the trial’s two treated groups was the same as in a group receiving a placebo. It failed to slow disease progression in RRMS patients enrolled in the Phase 3 CONCERTO trial. Also, the lower dose of the drug failed to meet the trial’s primary objective of slowing the progression of the disease. It also failed to meet secondary objectives of slowing the progression at six months and nine months.

However, laquinimod showed positive results in the trial that the companies will continue to pursue it as a treatment for other neurodegenerative diseases. For example, it reduced the risk of relapse in RRMS patients by 28%. It also led to a 40 percent, 15-month reduction in patients’ brain volume – a measure of disability progression – compared with a placebo. And it reduced the number of gadolinium-enhancing T1 lesions in the brain – a measure of inflammation – by 30 percent over the 15 months. Teva is evaluating the potential of laquinimod in PPMS and Huntington’s with the clinical trials (NCT02284568 and NCT02215616). CONCERTO trial results will be published in a scientific journal and presented at a medical meeting, the partners said.